Mana.bio
Seed
Mana.bio: An AI-driven startup specializing in LNP development for mRNA-based therapies and vaccines.
Founded
2021Mana.bio: An AI-driven startup specializing in LNP development for mRNA-based therapies and vaccines.
Mana.bio is an early-stage biotechnology company based in Tel Aviv, Israel, with a San Francisco presence. Its founders combine software entrepreneurship with deep expertise in nanomedicine and artificial intelligence.
The company's platform and Mina AI agent are positioned in the competitive LNP delivery space alongside Recode Therapeutics, Acuitas Therapeutics and other LNP technology providers. Key near-term milestones include expanding partnerships, advancing lead programs, and presenting additional preclinical data at scientific conferences.
The market for nucleic acid therapeutics and vaccines is expanding as mRNA, gene therapy and gene editing modalities mature. A major bottleneck is safe and effective delivery to tissues beyond the liver, creating demand for next-generation lipid nanoparticle platforms.
Mana.bio targets this opportunity with AI-enabled LNP discovery for extrahepatic delivery. If its predictive models and preclinical data translate to the clinic, the company could become a platform partner for biopharma developers of RNA medicines and genetic therapies.
Mana.bio's core advantage is the integration of machine learning with high-throughput LNP synthesis and screening, producing a closed-loop design-build-test-learn cycle. The platform is trained on a large curated LNP dataset and aims to predict safety, tropism and physicochemical properties.
This enables tissue-specific delivery beyond the liver, a key bottleneck for nucleic acid therapeutics. The company also offers Mina, a publicly available LLM-based AI agent for lipid nanoparticles that lowers the barrier for researchers to explore formulation insights.